The incidence of NTM (non tuberculous mycobacteria) pulmonary disease is increasing. The diagnosis must be established in the presence of clinical, radiological and microbiological findings. Groups at risk to contract pulmonary disease due to NTM ar...
The authors state that, on the basis of the present report, there is a correlation between clofazimine MICs and clinical outcome in NTM pulmonary disease.1 Although their data are intriguing, when viewed through the lens of the MIC principles listed earlier, it is clear that much more data ar...
Introduction: Despite the great clinical need, the development of drugs for treating non-tuberculous mycobacteria lung disease (NTM-LD), partly from the scientific difficulty, but also because the eventual size and types of markets for commercially-developed drugs has been unclear.Areas Covered: Here...
paratuberculosis (MAP) is an NTM that causes Johne's disease, an enteritis of ruminant animals. Humans are broadly exposed to MAP or its antigens in the environment and in food products from infected animals. MAP has also been implicated as an environmental trigger for a number of autoimmune ...
NTMlung diseasecolonisationprocalcitoninsTREM-1No abstract is available for this article.doi:10.1111/j.1469-0691.2011.03588.xP.UniversitéBastienUniversitéJohn Wiley & Sons, Ltd.Clinical Microbiology and InfectionBastien P. Leishmaniases control: what part for development and what part for research?
The molecule is also in Phase 2 clinical trials [38,39]. A very recent report shows that SPR 720 obtained an orphan disease status from FDA to treat non-tuberculosis mycobacteria (NTM) [40]. Figure 2. Two novel compounds that have entered clinical development (a) GSK070 and (b) SPR20...